HROW - HARROW, INC.
Region: US
Website: harrowinc.com
Employees: 180
IPO year: 2007
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing
Harrow Health, Inc. owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases.
Harrow Inc (HROW) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Initiatives
Harrow Inc (HROW) reports an 84% increase in Q4 revenue, driven by strong product performance and strategic programs, despite challenges in reporting and cash flow management.
Read moreHarrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results
NASHVILLE, Tenn., March 27, 2025--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, announced results for the fourth quarter and year ended December 31, 2024. The Company also posted its fourth quarter Letter to Stockholders and corporate presentation to the "Investors" section of its website, harrow.com. The Company encourages all Harrow stockholders to review these documents, which provide additional details concerning the historical quarterly period and future ex
Read moreHarrow To Report Fourth Quarter and Audited Year-End 2024 Financial Results After Market Close on March 27, 2025
NASHVILLE, Tenn., March 27, 2025--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it will report its fourth quarter and audited financial results for the year ended December 31, 2024, on Thursday, March 27, 2025, after the market close. The Company will also post its fourth quarter Letter to Stockholders to the "Investors" section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Frida
Read more